Abstract：
BACKGROUND: Tigecycline-associated hypofibrinogenemia has been reported as an important adverse effect in recent years, but controlled studies minimizing confounding factors are needed. The objective of our study was to assess changes in fibrinogen levels in patients for hospitalization, comparing two antibiotic episodes (tigecycline and other) within the same patients.
METHODS: The retrospective, self-controlled case series study was conducted at our University Hospitals. The study compared the change in fibrinogen levels during the patient\'s hospitalization for tigecycline (TigePer) and another antibiotic period (OtherPer). In addition, bleeding events, bleeding risk (determined by the IMPROVE bleeding risk score), as well as 15- and 30-day mortality rates between TigePer and OtherPer were compared.
RESULTS: The study enrolled 50 patients with 100 episodes of antibiotic treatment. The median age (interquartile range) of the patients was 68.5 (21.5) years, and 38 % were female. As compared to OtherPer, TigePer had a statistically significant reduction in fibrinogen levels (p < 0.001), with a hypofibrinogenemia rate of 40 % in TigePer as compared to 2 % in OtherPer (p < 0.001). TigePer demonstrated a significantly higher 15-day mortality rate (p = 0.006). No significant differences were observed between the two periods in terms of bleeding risk, rate of bleeding events, and 30-day mortality rate (p > 0.05).
CONCLUSIONS: Hypofibrinogenemia and other coagulopathies, without associated bleeding events, are more frequently observed in patients receiving tigecycline. Therefore, it is crucial for clinicians to monitor fibrinogen levels during tigecycline use.
METHODS: The retrospective, self-controlled case series study was conducted at our University Hospitals. The study compared the change in fibrinogen levels during the patient\'s hospitalization for tigecycline (TigePer) and another antibiotic period (OtherPer). In addition, bleeding events, bleeding risk (determined by the IMPROVE bleeding risk score), as well as 15- and 30-day mortality rates between TigePer and OtherPer were compared.
RESULTS: The study enrolled 50 patients with 100 episodes of antibiotic treatment. The median age (interquartile range) of the patients was 68.5 (21.5) years, and 38 % were female. As compared to OtherPer, TigePer had a statistically significant reduction in fibrinogen levels (p < 0.001), with a hypofibrinogenemia rate of 40 % in TigePer as compared to 2 % in OtherPer (p < 0.001). TigePer demonstrated a significantly higher 15-day mortality rate (p = 0.006). No significant differences were observed between the two periods in terms of bleeding risk, rate of bleeding events, and 30-day mortality rate (p > 0.05).
CONCLUSIONS: Hypofibrinogenemia and other coagulopathies, without associated bleeding events, are more frequently observed in patients receiving tigecycline. Therefore, it is crucial for clinicians to monitor fibrinogen levels during tigecycline use.
摘要：
背景：近年来，替加环素相关性低纤维蛋白原血症被报道为一种重要的不良反应，但需要将混杂因素最小化的对照研究。我们研究的目的是评估住院患者的纤维蛋白原水平变化，比较同一患者的两种抗生素发作（替加环素和其他）。
方法：回顾性研究，我们在大学医院进行了自我对照病例系列研究.该研究比较了患者住院期间使用替加环素（TigePer）和另一个抗生素（OtherPer）的纤维蛋白原水平的变化。此外,出血事件,出血风险（由改善出血风险评分确定），比较了TigePer和OtherPer之间的15天和30天死亡率。
结果：该研究招募了50名患者，其中100次抗生素治疗。患者的中位年龄（四分位距）为68.5（21.5）岁，38%是女性。与其他人相比，TigePer的纤维蛋白原水平有统计学意义的降低（p<0.001），TigePer的低纤维蛋白原血症率为40%，而OtherPer的低纤维蛋白原血症率为2%(p<0.001)。TigePer显示出明显更高的15天死亡率（p=0.006）。在出血风险方面，两个时期之间没有观察到显著差异。出血事件发生率,和30天死亡率（p>0.05）。
结论：低纤维蛋白原血症和其他凝血障碍，无相关出血事件,在接受替加环素的患者中更常见。因此,临床医生在使用替加环素期间监测纤维蛋白原水平至关重要.
方法：回顾性研究，我们在大学医院进行了自我对照病例系列研究.该研究比较了患者住院期间使用替加环素（TigePer）和另一个抗生素（OtherPer）的纤维蛋白原水平的变化。此外,出血事件,出血风险（由改善出血风险评分确定），比较了TigePer和OtherPer之间的15天和30天死亡率。
结果：该研究招募了50名患者，其中100次抗生素治疗。患者的中位年龄（四分位距）为68.5（21.5）岁，38%是女性。与其他人相比，TigePer的纤维蛋白原水平有统计学意义的降低（p<0.001），TigePer的低纤维蛋白原血症率为40%，而OtherPer的低纤维蛋白原血症率为2%(p<0.001)。TigePer显示出明显更高的15天死亡率（p=0.006）。在出血风险方面，两个时期之间没有观察到显著差异。出血事件发生率,和30天死亡率（p>0.05）。
结论：低纤维蛋白原血症和其他凝血障碍，无相关出血事件,在接受替加环素的患者中更常见。因此,临床医生在使用替加环素期间监测纤维蛋白原水平至关重要.
